SUBSTANCE USE-DISORDER PREVENTION THAT PROMOTES OPIOID RECOVERY AND TREATMENT (SUPPORT) FOR PATIENTS AND COMMUNITIES ACT
Amendments
Enact (H.R. 6), S6063 [6SE], S6193 [17SE], H5522, H5560, H5561, H5562, H5564, H5565, H5566 [22JN]
——— consideration (H. Res. 949), H5302 [20JN]
Bills and resolutions
Enact (see H.R. 6), H5151 [13JN]
Enact (H.R. 6): concur in Senate amendment (see H. Res. 1099), H9406 [28SE]
——— consideration (see H. Res. 949), H5283 [19JN]
E-Mails
Provisions: Advocates for Opioid Recovery (organization), H9252 [28SE]
Letters
Provisions: Carol Keehan, Catholic Health Association of the U.S., H9252 [28SE]
——— Corporate Health Care Coalition, H9250 [28SE]
——— James A. Klein, American Benefits Council, H9251 [28SE]
——— Peter Morris, Alex Dodd, David White, Jay Higham, and John Steinbrun, Opioid Treatment Program Consortium, H5561 [22JN]
——— several organizations, H9253 [28SE]
——— Suzanne P. Clark, U.S. Chamber of Commerce, H9252 [28SE]
——— Tom Van Coverden, National Association of Community Health Centers, H9251 [28SE]
Lists
Organizations supporting H.R. 6, provisions, H9243 [28SE]
Motions
Enact (H.R. 6), H5567 [22JN]
Remarks in House
Appalachian Regional Commission: allow funding to be used to address impacts of opioid addiction on workforce development and economic growth in Appalachia, H9249 [28SE]
CDC: reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use, H5518 [22JN]
Crime: establish criminal penalties for unlawful payments for referrals to recovery homes and clinical treatment facilities, H9244, H9249 [28SE]
DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment, H9248 [28SE]
Dept. of HHS: appoint a Federal Coordinator to coordinate opioid abuse reduction programs, serve as a liaison to State and local opioid reduction activities, and establish an electronic database on opioid abuse information, H9246 [28SE]
——— disseminate resources to early childhood care and education providers working with young children on ways to recognize and respond to children who may be impacted by trauma related to substance abuse, H9249 [28SE]
——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce, H9248 [28SE]
——— issue guidance relative to expedited approval of certain drugs, H5297 [20JN]
——— issue guidelines for prescribing naloxone, H5565, H5566 [22JN]
——— provide research on, and recommendations for, opioid prescribing practices for pregnant women, H5564, H5565 [22JN]
——— study and submit to Congress a report recommending how to improve use of non-opioid treatments for acute and chronic pain management for individuals under Medicare, H9249 [28SE]
——— survey organizations that provide substance use treatment services and submit plan to Congress to appropriate resources to address inadequacies in services or funding identified in survey, H5566, H5567 [22JN]
Drugs: authority of non-physician providers to prescribe buprenorphine for opioid use disorders, H5297 [20JN]
——— authorize, develop, and implement a coordinated tracking system of federally-funded initiatives and grant programs for substance abuse treatment, prevention, and enforcement, H9249 [28SE]
——— prohibit expansion of classes of health care workers who are authorized to dispense narcotics for narcotic treatment, H5561, H5562 [22JN]
——— provide access to medication-assisted treatment programs to reduce opioid addiction overdoses and relapses, H5522 [22JN]
——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, H5512, H5514 [22JN]
——— provide for additional residency positions to help combat opioid crisis, increase funding for opioid abuse crisis, and prohibit delays of generic drugs and biosimilar biological products, H5570 [22JN], E905 [25JN]
Enact (H.R. 6), H5380 [21JN], H5511–H5572 [22JN], H5755 [27JN], H9553 [16NO], E902 [22JN], E950 [28JN]
——— concur in Senate amendment (H. Res. 1099), H9156, H9174–H9255 [28SE]
——— consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]
——— motion to recommit, H5570 [22JN], E905 [25JN]
FDA: deter opioid abuse and addiction through development of high-quality, evidence-based opioid analgesic prescribing guidelines, H5563, H5564 [22JN]
Medicaid: allow States to provide medical assistance at a residential pediatric recovery center to infants under 1 year of age with neonatal abstinence syndrome and their families, H9156 [28SE]
——— allow States to provide services for certain individuals with opioid use disorders in mental institutions, H5515 [22JN], H9249 [28SE]
——— ensure health insurance continuity for former foster youth, H5515 [22JN]
——— protect enrollment of incarcerated youth for medical assistance, H5516 [22JN]
Medicare: cover opioid treatment program services, H5520 [22JN]
——— encourage use of non-opioid analgesics for management of post-surgical pain, H5513, H5514 [22JN]
——— modify payments for certain outpatient surgical services, H5512 [22JN]
——— provide for certain program integrity transparency measures, H9248 [28SE], E902 [22JN]
——— require e-prescribing for coverage under part D of prescription drugs that are controlled substances, H5512, H5514 [22JN]
——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, H5520 [22JN]
——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures, E902 [22JN]
——— require review of current opioid prescriptions for chronic pain and screening for opioid use disorder be included in initial preventive physical examinations, H5514 [22JN]
Medicare Payment Advisory Commission: report on opioid payment, adverse incentives, and tracking and monitoring data, H9553 [16NO]
NIH: expand unique research initiatives authority, H9246 [28SE]
Postal Service: require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs, H9248 [28SE]
U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments, H5515 [22JN]
Remarks in Senate
CDC: reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use, S6162 [17SE], S6463 [3OC]
Committee on the Judiciary (Senate): accomplishments, S7976 [20DE]
Comprehensive Addiction and Recovery Act: reauthorize and expand, S6050 [6SE], S6126 [12SE], S6170 [17SE]
Congress: accomplishments of the 115th Congress, S6785 [11OC], S7020 [15NO]
Crime: establish criminal penalties for unlawful payments for referrals to recovery homes and clinical treatment facilities, S6473 [3OC]
DEA: allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals, S6472 [3OC]
——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse, S6174 [17SE]
——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders, S6471 [3OC]
Dept. of HHS: authorize a loan repayment program for substance use disorder treatment employees, S6471 [3OC]
——— develop national milestones to measure success in curtailing the opioid epidemic, S6162 [17SE], S6463 [3OC]
——— establish a grant program to create comprehensive opioid recovery centers, S6164 [17SE], S6471 [3OC]
——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce, S6116 [12SE], S6198 [18SE]
——— improve State response to opioid abuse crisis by prioritizing State Targeted Response to the Opioid Crisis Grants to States with high overdose mortality rates and lack of access to treatment, S6471 [3OC]
——— improve treatment and early interventions for pregnant and postpartum women and infants affected by substance use disorder, S6198 [18SE]
——— provide for sharing of health information concerning an individual’s substance abuse history and treatment by certain entities, S6177 [17SE], S6472 [3OC]
——— study and submit to Congress a report recommending how to improve use of non-opioid treatments for acute and chronic pain management for individuals under Medicare, S6470 [3OC]
Dept. of Homeland Security: improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S., S6436 [2OC]
Dept. of Transportation: improve controlled substances and alcohol testing, S6210 [18SE]
Depts. of Labor and HHS: establish a pilot program to award competitive grants to counties and tribal entities to administer combined workforce training and drug addiction treatment and recovery programs, S6471 [3OC]
Drugs: address trafficking of illicit fentanyl, S6049 [6SE]
——— extend authority of nurse practitioners to provide medication-assisted treatment for opioid use disorders, S6163 [17SE]
——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment, S6164 [17SE]
——— improve prosecution of the sale and distribution of synthetic drugs known as analogues, S6473 [3OC]
——— prevent substance abuse and reduce demand for illicit narcotics, S6120 [12SE]
——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, S6162 [17SE], S6463, S6469 [3OC]
——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising, S6173 [17SE]
Enact (H.R. 6), S4376 [25JN], S4380 [26JN], S6048–S6050 [6SE], S6116–S6121, S6126, S6149 [12SE], S6159–S6170, S6172–S6178 [17SE], S6198, S6210, S6215–S6217, S6218 [18SE], S7177 [28NO]
——— House amendment, S6432–S6436 [2OC], S6456, S6459, S6463, S6467, S6468–S6474, S6477–S6484, S6489, S6491 [3OC], S6796–S6798 [11OC]
——— unanimous-consent agreement, S6105 [6SE], S6457 [3OC]
FDA: provide for accelerated approval of non-opioid or non-addictive pain medications and treatments for substance use disorders, S6470 [3OC]
FTC: prohibit marketing of bogus opioid treatment programs or products, S6471 [3OC]
Medicaid: allow States to provide medical assistance at a residential pediatric recovery center to infants under 1 year of age with neonatal abstinence syndrome and their families, S6050 [6SE], S6127 [12SE], S6170 [17SE], S6436 [2OC], S6472 [3OC], S6797 [11OC]
——— allow States to provide services for certain individuals with opioid use disorders in mental institutions, S6174 [17SE], S6480–S6482 [3OC]
——— provide for a demonstration project to increase substance use provider treatment capacity, S6169 [17SE]
——— require States to suspend, rather than terminate, an individual’s eligibility for medical assistance while such individual is an inmate of a public institution, S6463 [3OC]
Medicare: expand use of telehealth services for treatment of opioid use disorder and other substance use disorders, S6210 [18SE]
Mental health: address psychological, developmental, social, and emotional needs of children, youth, and families who have experienced trauma, S6174 [17SE]
Postal Service: require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs, S6049 [6SE], S6215–S6217 [18SE], S6432, S6436 [2OC], S6471, S6473 [3OC], S6797 [11OC]
U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments, S6127 [12SE], S6169 [17SE], S6469, S6489 [3OC]
Reports filed
Consideration of H.R. 6, Provisions: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]
Statements
Provisions: American Society of Addiction Medicine, H9252 [28SE]
——— National Association for Behavorial Healthcare, H9251 [28SE]
——— Simona Combi, First Focus Campaign for Children (organization), H9250 [28SE]
Texts of
H. Res. 949, consideration of H.R. 6, provisions, H5294 [20JN]
H. Res. 1099, concur in Senate amendment to H.R. 6, provisions, H9174–H9242 [28SE]